← Leaderboards
Herbert I Hurwitz
Duke University
$4,193,162
Attributed
$4,664,717
Total exposure
8
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $591.1K · FY2005–15$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
Funding mix
By agency
NIH$4,664,717 · 8
By mechanism
R01$2,149,392 · 1
UM1$707,333 · 1
K23$652,455 · 1
K24$613,304 · 1
R21$542,233 · 1
M01$0 · 3
Top collaborators
- Elizabeth C Dees2 shared
- Albert Craig Lockhart2 shared
Most similar at Duke University
Same institution · by research overlap
- Michael Barry Kastan$65,974,699
- John H Sampson$43,413,436
- James L Abbruzzese$10,558,825
- Debra A. Schwinn$11,466,054
- Robert J Lefkowitz$17,365,480
Others in their field
Top investigators on “Angiogenesis”
- David Heimbrook · Leidos Biomedical Research, Inc.$75,067,502
- Steven Terry Rosen · Beckman Research Institute/City Of Hope$59,567,306
- Martin Friedlander · Scripps Research Institute$48,350,175
- Larry Arthur$33,866,306
- Michael Simons · Yale University$30,647,106
- Henry Shelton Earp · Univ Of North Carolina Chapel Hill$29,372,588
Research focus
AngiogenesisClinical ResearchBiopsyWound HealingAngiogenesis InhibitorsHuman SubjectBiomarkerCancer TherapyVascular Endothelial Growth FactorsBaseTissuesTumorPharmaceutical PreparationsNeoplasm /Cancer ChemotherapyResearch PersonnelFutureMolecularMolecular ProfilingResponseClinical Trial Phase IBiologyAffectDermalAngiogenic Factor
Grant awards (26)
Duke-UNC-Wash U Partnership for Early Phase Clinical Trials in Cancer$201,163
UM1 · FY2015 · CA · contact PI
Duke-UNC-Wash U Partnership for Early Phase Clinical Trials in Cancer$506,170
UM1 · FY2014 · CA · contact PI
Anti-VEGF in Tumors & Wounds: Efficacy vs Toxicity$464,274
R01 · FY2010 · CA · contact PI
Wound Angiogenesis as a Biomarker for Tumor Angiogenesis$126,778
K24 · FY2010 · CA · contact PI
Anti-VEGF in Tumors & Wounds: Efficacy vs Toxicity$458,281
R01 · FY2009 · CA · contact PI
Wound Angiogenesis as a Biomarker for Tumor Angiogenesis$124,659
K24 · FY2009 · CA · contact PI
Anti-VEGF in Tumors & Wounds: Efficacy vs Toxicity$439,335
R01 · FY2008 · CA · contact PI
Wound Angiogenesis as a Biomarker for Tumor Angiogenesis$122,601
K24 · FY2008 · CA · contact PI
Anti-VEGF in Tumors & Wounds: Efficacy vs Toxicity$376,466
R01 · FY2007 · CA · contact PI
Wound Angiogenesis as a Biomarker for Tumor Angiogenesis$120,603
K24 · FY2007 · CA · contact PI
Anti-VEGF in Tumors & Wounds: Efficacy vs Toxicity$411,036
R01 · FY2006 · CA · contact PI
Wound Angiogenesis as a Biomarker for Tumor Angiogenesis$118,663
K24 · FY2006 · CA · contact PI
NEW CLINICAL BIOMARKER FOR CANCER--WOUND ANGIOGENESIS$65,245
K23 · FY2005 · CA
Does NO mediate clinical anti-VEGF vascular effects$274,120
R21 · FY2004 · CA
NEW CLINICAL BIOMARKER FOR CANCER--WOUND ANGIOGENESIS$130,491
K23 · FY2004 · CA
Does NO mediate clinical anti-VEGF vascular effects$268,113
R21 · FY2003 · CA
NEW CLINICAL BIOMARKER FOR CANCER--WOUND ANGIOGENESIS$130,491
K23 · FY2003 · CA
NEW CLINICAL BIOMARKER FOR CANCER--WOUND ANGIOGENESIS$65,246
K23 · FY2002 · CA
NEW CLINICAL BIOMARKER FOR CANCER--WOUND ANGIOGENESIS$130,491
K23 · FY2001 · CA
NEW CLINICAL BIOMARKER FOR CANCER--WOUND ANGIOGENESIS$130,491
K23 · FY2000 · CA
Evaluate potential surrogate markers of angiogenesis in normal volunteers$0
M01 · FY2000 · RR
Evaluate potential surrogate markers of angiogenesis in normal volunteers$0
M01 · FY2000 · RR
Phase I trial to evaluate the safety &tolerability of topoisomerase I inhibitor$0
M01 · FY2000 · RR
Phase I trial to evaluate the safety &tolerability of topoisomerase I inhibitor$0
M01 · FY2000 · RR
Surrogate markers of angiogenesis in patients treated with anti-angiogenic agents$0
M01 · FY2000 · RR
Surrogate markers of angiogenesis in patients treated with anti-angiogenic agents$0
M01 · FY2000 · RR